X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://pharmaphorum.com/news/cstone-gets-a-win-for-sugemalimab-in-oesophageal-cancer/
https://www.pharmatimes.com/news/eqrx_receives_mhra_marketing_approval_for_sugemalimab_1484724
https://www.prnewswire.com/news-releases/cstone-presents-updated-results-of-a-registrational-study-of-sugemalimab-in-patients-with-stage-iii-nsclc-via-oral-presentation-at-wclc-2022-301601233.html
https://www.fiercepharma.com/pharma/pfizer-partner-cstone-explores-sale-us-path-blocked-chinese-competition-heats-bloomberg
https://www.asiaone.com/business/cstone-and-pfizer-announce-nmpa-approval-sugemalimab-patients-unresectable-stage-iii-non
https://www.prnewswire.com/news-releases/cstone-announces-first-patient-enrollment-in-the-us-in-the-phase-1-clinical-trial-of-cs5001-a-potential-global-best-in-class-ror1-targeting-adc-301513912.html
https://www.asiaone.com/business/cstone-announced-two-key-phase-3-registrational-clinical-trials-sugemalimab-completed
https://www.prnewswire.com/news-releases/cstone-announces-the-gemstone-302-study-of-sugemalimab-met-the-endpoint-of-overall-survival-in-the-first-line-treatment-of-metastatic-non-small-cell-lung-cancer-patients-301462818.html
https://endpts.com/eqrx-adds-armor-to-its-discount-checkpoint-inhibitor-submission-nailing-survival-mark-in-key-study/
https://www.asiaone.com/business/cstone-announces-clinical-data-registrational-study-sugemalimab-stage-iii-non-small-cell
Market Place
Share 
